Status:
COMPLETED
Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD
Lead Sponsor:
Regado Biosciences, Inc.
Conditions:
Healthy Volunteer
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This was a Phase 1a, single-center, double-blind, randomized, placebo-controlled study of the safety, tolerability, PK, and PD of single ascending doses of RB006 administered as an SC injection, with ...
Eligibility Criteria
Inclusion
- An Institutional Review Board (IRB)-approved informed consent was signed and dated prior to any study-related activities.
- Subject was between the ages of 18 and 45 years, inclusive.
- Subject was a female with a negative urine or serum pregnancy test or postmenopausal for at least 1 year prior to randomization.
- Subject had a body mass index (BMI) between 18 kg/m2 and 32 kg/m2 (weight/\[height\]2) and was ≥50 kg and ≤120 kg total body weight.
- Subject had normal (or abnormal and clinically insignificant) laboratory values at Screening.
- Subject was medically normal with no significant abnormal findings at the Screening physical examination.
- Subject had the ability to understand the requirements of the study and a willingness to comply with all study procedures.
- Subject had not consumed and agreed to abstain from taking any dietary supplements or nonprescription drugs
- Subject had not consumed and agreed to abstain from taking any prescription drugs
- Subject had not consumed alcohol-containing beverages for 3 days prior to CRU admission
- Subject had not consumed grapefruit or grapefruit juice within the 14 days prior to CRU admission
- Subject had not used tobacco or nicotine-containing products within 6 months prior to CRU admission
Exclusion
- Evidence or history of clinically significant oncologic, pulmonary, hepatic, gastrointestinal (GI), cardiovascular, hematologic, metabolic, neurological, immunologic, nephrologic, endocrine, or psychiatric disease.
- Any evidence or history of intracranial bleeding, aneurysm, or thrombotic or hemorrhagic stroke.
- Any known individual or family history of a bleeding diathesis or coagulopathy.
- Active or expected menstruation during the Treatment Phase (females only).
- History of thrombocytopenia associated with abnormal bleeding or risk of a bleeding event, or screening or baseline platelet count \<100,000/mm3.
- History of thrombocytosis associated with a thrombotic event or risk for a thrombotic event, or screening or baseline platelet count \>600,000/mm3.
- Endoscopically confirmed peptic ulcer disease within 3 years of CRU admission or GI bleeding within 3 months of CRU admission, including a positive stool for occult blood at Screening or Baseline.
- Urinary tract bleeding within 3 months of CRU admission, including microscopic hematuria on screening or baseline urinalysis.
- Unusual or prolonged bleeding (e.g., gum bleeding, nosebleeds, easy bruising), as documented on the Self-Reported Bleeding Questionnaire, at Screening.
- Severe trauma, fracture, major surgery, or biopsy of a parenchymal organ within 3 months of CRU admission.
- Severe persistent hypertension (systolic pressure \>180 mmHg or diastolic pressure \>110 mmHg).
- Baseline hemoglobin \<12.0 g/dL for males or \<11.0 g/dL for females; prothrombin time (PT) greater than the ULN; or aPTT greater than the ULN.
- Clinically significant liver dysfunction (e.g., as evidenced by elevated liver function tests).
- Clinically significant renal dysfunction (e.g., estimated glomerular filtration rate \<60 mL/min or serum creatinine \>1.5 mg/dL).
- History of illicit drug abuse in the past year or current evidence of such abuse in the opinion of the Investigator.
- Positive findings on urine drug screen.
- Positive findings for human immunodeficiency virus, hepatitis B, and/or hepatitis C at Screening.
- Pregnant or lactating.
- Acute illness within 1 week of CRU admission.
- A history of alcohol abuse in the past year relative to CRU admission.
- Donated plasma within 7 days of study drug administration.
- Donated 1 or more pints of blood (or equivalent blood loss) within 6 weeks prior to study drug administration.
- Use of an investigational drug within 30 days prior to CRU admission or prior REG1 Anticoagulation System exposure.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01872572
Start Date
August 1 2009
End Date
December 1 2009
Last Update
June 7 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PPD Development, LP
Austin, Texas, United States, 78744